About Avance Clinical
More than three decades of deep clinical research management experience
Avance Clinical is the largest specialist Australian and US CRO delivering quality clinical trials in Australia, New Zealand and North America for international biotechs.
The CRO has been delivering clinical drug development services for international biotechs for FDA and EMA regulatory approval, for more than three decades.
WHY BIOTECHS
CHOOSE
AVANCE CLINICAL
Globally accepted data
Avance Clinical has a world-class reputation for quality data.
Extend budget by 43.5%
Avance Clinical can secure the maximum rebate on your clinical trial spend.
Rapid start-up
Avance Clinical can deliver Site Initiation Visit (SIV) and Study Start in 5 – 6 weeks.
Latest technology
Avance Clinical invests heavily in industry-leading technology platforms.
Avance Clinical Benefits
The CRO has been delivering clinical drug development services for international
biotechs for FDA and EMA regulatory approval, for more than three decades.
Learn more about Avance Clinical
Full Service CRO
Avance Clinical is the leading full-service CRO for international biotechs conducting Early Phase clinical trials.
The latest technology for data compliance
The company has focussed on state-of-the-art technology and systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, and Medrio are just some of the technology partners.
Early to Late phase
Avance Clinical Australia and New Zealand teams focus on servicing biotech clients in their early phases of drug development delivering fast, nimble, and adaptive client-oriented solutions. In collaboration with our US operations, we also deliver later-phase CRO services.
Fast, nimble, and adaptive solutions
Avance Clinical delivers customized solutions designed around specific client needs rather than a one size fits all approach.
ClinicReady Success Story
Tetherex Pharmaceuticals
"The Avance team demonstrated flexibility and a solution-oriented attitude in working with us towards obtaining rapid ethics approval, thereby facilitating trial initiation in a timely and efficient manner." - Dr. Russell Rother, President and Chief Operating Officer
